DRUGS GROW AT A SNAIL'S PACE

APRIL 01, 2008

IMS Health?s annual US Pharmaceutical Market Performance Review showed that the sales of Rx drugs in the United States only grew 3.8% in 2007, compared with 8% seen in 2006. It is the lowest growth rate since 1961.

The total US Rx drug sales hit $286.5 billion last year, with the declining growth rate partly attributed to expirations of patents on lucrative medicines, which paved the way for cheaper generic versions. IMS Health also cited fewer new product approvals, safety concerns, and the leveling of year-to-year growth from the Medicare Part D program.

The brand name drugs with approximately $17 billion in sales lost patent protection in 2007, opening the door to a 10% growth for generic medicines. IMS Health found that generic drugs were responsible for 67% of US prescription drugs dispensed in 2007. The company predicts compound annual US pharmaceutical sales growth of 3% to 6% through 2012. The group noted that new biotech drugs and vaccines as well as the estimated launch of a small group of drugs with a potential of at least $1 billion a year will help offset major patent expirations.




SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.